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RESEARCH
pCLIF-SOFA is a reliable outcome 
prognostication score of critically ill children 
with cirrhosis: an ESPNIC multicentre study
Caroline Claude1, Akash Deep2, Martin Kneyber3, Salman Siddiqui2, Sylvain Renolleau4, Luc Morin1, 
Emmanuel Jacquemin5, Jean‑Paul Teglas6, Vincent Gajdos6, Pierre Tissières1,7* , Philippe Durand1 on behalf of 
the ESPNIC liver failure, support working group8
Abstract 
Background and aims: Data on outcome of critically ill children with cirrhosis are scarce. We aimed to evaluate the 
prognostic accuracy of sequential organs scoring systems in children with cirrhosis admitted to Paediatric Intensive 
Care Units (PICU).
Methods: We performed a multicentre retrospective analysis of children with cirrhosis admitted into four European 
PICUs between 2011 and 2016. Investigators were members of the ESPNIC liver failure and support working group. 
Paediatric End‑Stage Liver Disease (PELD) and paediatric chronic liver failure sequential organ failure assessment score 
(pCLIF‑SOFA) diagnostic accuracy for 28‑ and 60‑day liver transplantation, 28‑day mortality and 60‑day composite 
outcome (ie. death or liver transplantation) were tested.
Results: One‑hundred‑and‑thirty children were included. The main causes for PICU admission were acute‑on‑
chronic liver failure (ACLF), gastrointestinal bleeding and sepsis. Twenty‑nine percent died and 22.3% were trans‑
planted by day‑60 after PICU admission. On multivariable analysis, pCLIF‑SOFA was the only predictor of mortality at 
day‑28 and of composite outcome. Both pCLIF‑SOFA and ACLF were independently associated with emergent liver 
transplantation. The pCLIF‑SOFA score higher than 9 well predicted a 28‑day mortality with a sensitivity of 87.8% and 
a specificity of 77.3%. A pCLIF‑SOFA score higher than 7 was independently associated with liver transplantation on 
day‑60. Stage 3 AKI assessed with KDIGO classification was significantly associated with 28‑day mortality.
Conclusions: Half of critically ill cirrhotic children admitted to PICU either died or were transplanted within the initial 
28‑day period. On admission pCLIF‑SOFA score accurately identify patients transplanted at day‑28 and day‑60 to 
those alive without LT and is associated with 28‑day mortality and composite outcome at day‑60.
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Introduction
Cirrhosis still remains a life-threatening condition in the 
era of liver transplantation and several complications 
involving organ failures, gastrointestinal bleeding, and 
septic shock may impair outcome [1]. In adults, many 
clinical studies report a poor prognosis in critically ill cir-
rhotic adult patients requiring ICU admission [2]. Paedi-
atric liver diseases have seen their prognosis challenged 
due to the progress of liver transplantation (LT) [3]. In 
Europe, the indications for paediatric LT are mainly 
chronic liver diseases, with metabolic and cholestatic 
diseases encompassing the majority of causes. Although 
there is paediatric data on global and long-term prog-
nostication of various cause of liver disease, there is lit-
tle data specifically on cirrhosis in children admitted to 
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Paediatric Intensive Care Unit (PICU) while awaiting 
LT. Delay on LT list enrolment has shown to be corre-
lated with outcome in infants [4]. Pre-transplantation 
complications arise mainly at the cirrhosis stage. Death 
of children with acute decompensated cirrhosis has been 
reported to be of 33% and mortality increases with the 
number of failing organs [5, 6]. A better understanding 
of the clinical pathway and unfavourable outcome in cir-
rhotic children, especially when admission to PICU is 
needed, could improve medical management as well as 
organ allocation prioritization in these children. In the 
present study, we aim to describe the characteristics of 
cirrhotic children admitted in four European PICUs and 
assess sequential organ failure scores in regard to mortal-
ity, liver transplantation at days 28 and 60.
Materials and methods
Patients and outcomes
We performed a retrospective multicentre study of all 
children less than 18  years old with non-transplanted 
cirrhosis admitted to PICU between January 2011 and 
January 2016 in four paediatric liver transplantation cen-
tres (France, United Kingdom, Netherlands). Patients 
were identified using institutional electronic database. 
The diagnosis of cirrhosis was based on previous liver 
biopsy findings or a composite of clinical, laboratory and 
imagery data in accordance with published guidelines at 
the discretion of staff hepatologist [7]. The project was 
approved by the French Intensive Care Ethic Committee 
(CE SRLF 19–21) and was granted a waiver of informed 
consent. The primary endpoint was, in survivors at day-
28, LT at day-28. The three secondary outcomes studied 
were (1) in survivors at day-60, LT at day-60; (2) mortality 
at day-28; (3) a combined criterion including LT or death 
at day-60. In addition, role of acute-on-chronic liver fail-
ure (ACLF), sepsis, centre and presence of comorbidities 
will be assessed. Day-28 and day-60 included PICU or 
Hospital data.
Data collection
We collected standard data on history, main indica-
tions for PICU admission, physical examination, labora-
tory measurements at admission and day-7, and adverse 
events until discharge from the PICU and from the hos-
pital. All collected data were available in all four centres. 
Aetiologies were classified as metabolic, infectious, drug-
related, auto-immune or cholestatic diseases. Compli-
cations due to cirrhosis pre-existing to PICU admission 
were reported: growth failure, osteopenia, portal hyper-
tension including variceal-bleeding history, spontaneous 
bacterial peritonitis (SBP), hepato-pulmonary syndrome, 
hepatopulmonary syndrome (HPS), porto-pulmonary 
hypertension, or hepatocellular carcinoma. Reason for 
admissions included ACLF, gastrointestinal (GI) bleed-
ing, sepsis, cardio-respiratory failure, acute kidney injury, 
neurologic failure. The adverse events during PICU stay 
were recorded if they were different from the admission 
indication. These included acute kidney injury (AKI), 
sepsis, hepatic encephalopathy (HE) and its grading 
according to the Trey classification, bleeding, metabolic 
disturbances (hypoglycaemia, hyperammonemia), death 
or LT. The variables collected were used to compute one 
score of severity at admission (PIM2: Paediatric Index of 
Mortality 2), two scores of organ failure during the first 
24 h: PELD, pCLIF-SOFA [5, 8, 9] (Additional file 1), and 
worst KDIGO (Kidney Disease Improving Global Out-
comes) classification during hospitalization [10].
Definitions
Acute-on-chronic liver failure (ACLF) was defined as an 
impairment of hepatic functions in cirrhotic patients, due 
to a triggering factor and resulting in at least two organ 
failures (European Association for the Study of Liver-
Chronic Liver Failure, EASL-CLIF definition) [11]. AKI 
was defined according to KDIGO definition into three 
stages [10]. Sepsis was defined following the Sepsis-3 
definition with a paediatric adaptation of organ failures 
criterion according to Goldstein, as an infection with two 
or more organ failures [12, 13]. On admission, patients 
with ACLF triggered by sepsis were classified as ACLF. 
Pathogen and sites of infection (pneumonia, urinary 
tract infection, SBP, cholangitis, primary bloodstream 
infection, meningitis or catheter-related bloodstream 
infection) were reported. GI tract bleeding, neurological 
impairment (cerebral oedema, HE, or seizures), acute res-
piratory and hemodynamic failure were also considered.
Statistical analysis
The demographic and clinical characteristics of patients 
were assessed for normality using Kolmogorov–Smirnov 
test and expressed as numbers and percentages for binary 
or ordinary data and median and interquartile range 
(IQR) for continuous data. To evaluate predictors of out-
come, in addition to calculated scores, clinically pertinent 
criterion from admission time (total bilirubin, INR, pres-
ence of comorbidities, centre) and during the stay (sepsis, 
ACLF) were selected. For multivariable analysis, pCLIF-
SOFA, ACLF, sepsis, centre and presence of comor-
bidities were included. The t-test was used to compare 
continuous variables between two different groups and 
Chi-square was used to compare categorical variables 
(or exact Fisher test when expected values are less than 
5). The prognostic performances of the both PELD and 
pCLIF-SOFA score were compared by drawing a receiver 
operating characteristic curve and the area under the 
curve (AUC) calculated through logistic linear predictors. 
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The best thresholds were obtained with the calculation 
of sensitivity, specificity, positive and negative predic-
tive values and the Youden’s index (sensitivity + specific-
ity-1). We used logistic regression to estimate odd ratios 
(OR) and 95% confidence intervals (95% CI). Logistic 
regression multivariable analysis using a descending 
incremental (or a backward elimination) method with a 
stopping threshold of 0.2 was used to identify independ-
ent predictors for each outcome. For all analysis, sur-
vival without LT was considered as reference. Survival of 
patients according to KDIGO score have been evaluated 
by Kaplan–Meier curves and these later have been tested 
using log-rank test. Centres effect on mortality has been 
tested using Cox regression. All analyses were conducted 




A total of 130 patients were enrolled with a median age 
of 41 [1–200] months. The majority (n = 120, 92.2%) had 
either a metabolic or a cholestatic (including biliary atre-
sia) cirrhosis. The main reason requiring PICU admission 
was GI tract bleeding (42/130, 32.3%) followed by ACLF 
(23/130, 17.7%) and sepsis (24/130, 18%). In addition, 
6/23 patients with ACLF had a concomitant sepsis at 
admission. Patient’s clinical and biological characteristics 
on admission are shown in Table 1.
The median PICU stay was 13 [2–17] days. At day-
28, 33/130 (25.4%) patients died, and 22/130 (16.9%) 
received an emergent LT. At day-60, a total of 29/130 
patients (22.3%) were transplanted, of those none died, 
and 63/130 (48.5%) patients survived without LT (Fig. 1). 
During the whole PICU hospitalization, sepsis (includ-
ing 30 from admission) occurred in 64/130 (49.2%), 
26/64 (40.6%) of those were in septic shock. Although 
identified in univariate model, sepsis was not associ-
ated with primary and secondary outcomes on multi-
variable analysis. Bacterial infections accounted for the 
majority of sepsis and Gram-negative bacteria were the 
most common yielded pathogens (41% identified). The 
main site of infection was SBP (27%) followed by cathe-
ter-related bloodstream infection (24%). Most children 
(103/130, 79.2%) required mechanical ventilation dur-
ing their stay, 35/103 from admission and 68/103 during 
their stay, respectively. Of these 103 ventilated patients, 
33 (32%) died on the 60th day. Two out of eight patients 
were known to have hepato-pulmonary syndrome on 
admission, died. Regarding renal failure, 23/130 (17.7%) 
developed stage 3 AKI and 15/130 (11.5%) patients were 
dialysed during PICU stay of whom 7/15 (46.7%) died. 
The Kaplan–Meier survival curve at day-28 showed a sig-
nificant survival difference between the three groups: no 
AKI, stage 1 + 2, and stage 3 (log-rank p = 0.0001; Addi-
tional file 2). No centre effect on day-28 and day-60 mor-
tality was found (respectively, p = 0.18 and p = 0.12; Cox 
regression analysis).
Predictors of outcome
Out of the three tested scores, only PIM2 failed to 
show a significant difference in all primary and second-
ary outcomes (Additional file  3). Unsurprisingly, both 
Table 1 Characteristics and  severity parameters 
of patients at admission
BA biliary atresia, ACLF acute-on-chronic liver failure, GI gastro-intestinal, INR 
International Normalized Ratio, pCLIF-SOFA Paediatric Chronic Liver Failure-
Sequential Organ Failure Assessment score, PELD paediatric end-stage liver 
disease, KDIGO Kidney Disease Improving Global Outcomes, PIM2 Paediatric 
Index of Mortality 2, PICU-LOS paediatric intensive care unit-length of stay
a Median [IQR] or number (percentage) as appropriate
Characteristics Valuea
Centres
 Centre 1 38 (29.2%)
 Centre 2 33 (25.5%)
 Centre 3 31 (23.8%)
 Centre 4 28 (21.5%)
Cause of cirrhosis
 Metabolic 28 (21.5%)
 Cholestatic including BA 92 (70.7%)
 Auto‑immune 4 (3%)
 Drug 4 (3%)
 Infectious 2 (1.5%)
Female 58 (44.6%)
Age (months) 41 [1.0; 200]
Weight (kg) 8.7 [6.0; 18.5]
Reason for admission
 ACLF 23 (17.7%)
 GI bleeding 42 (32.3%)
 Neurological 4 (3%)
 Respiratory 18 (13.8%)
 Sepsis 24 (18.4%)
 Other 19 (14.6%)
Bilirubin (µmol/L) 216 [89; 403]
INR 1.89 [1.2; 3.42]
pCLIF‑SOFA score 8.6 [0; 21]
PELD score 18.6 [– 14.7; 47.9]
KDIGO stage (1 + 2, 3) 17 (13%), 23 (17.7%)
PIM2 score 13.4% [12;4; 14.4]
Mechanical ventilation 35 (27%)
Sepsis and septic shock (admission + hospitaliza‑
tion)
30 + 34 (49.2%)
 Sepsis 38 (59.4%)
 Septic shock 26 (40.6%)
PICU‑LOS (days) 13 [2; 17]
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pCLIF-SOFA and PELD showed a similar diagnostic 
performance with all outcomes (Fig.  2). This is closely 
related to the fact that the two PELD criteria (total bili-
rubin and INR) with the higher impact on scoring are 
included in the pCLIF-SOFA score. Considering that 
pCLIF-SOFA score better describe conditional organ 
failures which is of specific relevance for acutely ill cir-
rhotic patients admitted in PICU, we further tested only 
the pCLIF-SOFA. On multivariable analysis, ACLF and 
pCLIF-SOFA were both independently associated with 
the primary outcome (Table  2). On day-28 and day-60, 
a pCLIF-SOFA ≥ 7 had a sensibility and specificity for 
liver transplantation of 77.3%¨/44% and 75.9%/47.6%, 
respectively. Performance of pCLIF-SOFA for identify-
ing patients with day-28 mortality was high [AUC ROC 
0.83 (95% CI 0.74–0.93), p < 0.001]. Best cut-off value for 
day-28 mortality prediction was 9 with a sensitivity of 
87.8% and specificity of 77.3%. On multivariable analysis, 
pCLIF-SOFA ≥ 7, ACLF and presence of comorbidities 
were associated with emergent LT at day-60 (Table  3), 
whereas only pCLIF-SOFA remained associated with 
mortality at day-28 (Table 4) and composite outcome at 
day-60 (Table 5). No centre effect was found for primary 
outcome (LT day-28, p = 0.34; LT day-60, p = 0.13) nor 
for the composite outcome (p = 0.44).
Discussion
To our knowledge, this is the first study evaluating the 
characteristics and prognostic factors of a large multi-
center cohort of non-transplanted cirrhotic critically ill 
children admitted to the paediatric intensive care unit. 
This retrospective study of four large European Paediatric 
LT centres provided us a comprehensive clinical and bio-
logical description of 130 patients admitted over a 5-year 
period. The main finding is the accuracy of on admis-
sion pCLIF-SOFA score for identifying, among survivors, 
patients transplanted at day-28 and day-60. On multivar-
iable analysis, pCLIF-SOFA was associated with 28-day 
mortality and composite outcome at day-60.
The high mortality rates observed at day-28 and 
60, respectively, of 25.4% and 29.2%, were consistent 
with published adult data. Adult cohorts of cirrhotic 
Fig. 1 Flowchart of the 130 children with acute decompensated chronic liver disease admitted in PICU and outcomes analysis. *No death in liver 
transplanted patients. Outcome analysis: primary outcome: group 1 versus group 2; secondary outcome 1: group 4 versus group 5; secondary 
outcome 2: group 3 versus group 2; secondary outcome 3: groups 4 + 6 versus group 5. LT, liver transplantation
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Fig. 2 Receiver operating characteristics curves showing the discrimination ability of the pCLIF‑SOFA and PELD scores in predicting liver 
transplantation on day‑28, day‑60, 28‑day mortality, and 60‑day composite outcome. All comparisons were against survival without liver 
transplantation
Table 2 Risk factors for liver transplantation (n = 22) versus survival without (n = 75) on day-28
Odds ratio are expressed as 95% (confidence interval). On multivariable analysis, centre effect was not significant (p = 0.20)
ACLF acute-on-chronic liver failure, BA biliary atresia, INR International Normalized Ratio, pCLIF-SOFA Paediatric Chronic Liver Failure-Sequential Organ Failure 
Assessment score, PELD paediatric end-stage liver disease
Characteristics Univariate analysis Multivariable analysis
Odds ratio p value Odds ratio p value
Comorbidity 0.18 (0.06–0.56) 0.003 0.03 (0.00–0.53) 0.017
Growth failure 0.80 (0.26–2.48) 0.711
ACLF 17.75 (4.79–65.7) 0.000 6.12 (1.06–35.03) 0.042
Sepsis 1.58 (0.60–4.12) 0.344
Biliary atresia 1.79 (0.67–4.12) 0.241
INR ≥ 2.5 5.22 (1.88–14.5) 0.001
Bilirubin ≥ 300 μmol/L 2.88 (1.00–8.30) 0.050
pCLIF‑SOFA 1.21 (1.04–1.40) 0.011 1.3 (1.04–1.67) 0.019
PELD 1.06 (1.01–1.11) 0.009
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patients admitted to intensive care displayed a mortal-
ity ranging from 31 to 40% [14, 15]. In a meta-analy-
sis of 13 adult series, overall intra-hospital mortality 
at 6  months reaches 75% [1]. Unlike decompensated 
cirrhosis, ACLF, a syndrome characterized by acute 
impairment of liver function in response to various 
kinds of insults in cirrhotic patients, has a very high 
short-term mortality. Importantly, two definitions of 
ACLF currently coexist. The Asia Pacific Association 
for the Study of Liver Diseases (APASL) defined ACLF 
as an acute liver injury complicating within four weeks 
of ascites and/or HE [16]. The EASL-CLIF consortium 
(EASL-CLIF Acute-on-chronic Liver Failure in Cir-
rhosis, CANONIC) proposed ACLF definition as an 
impairment of hepatic functions in cirrhotic patients, 
due to a triggering factor and resulting on at least two 
organs failure. Considering that the components of 
SOFA score (liver, kidney, brain, coagulation, circula-
tion and lungs) did not take into account specific char-
acteristics of patients with liver disease, the CANONIC 
study group adapted it to predict short-term mortality 
in liver cirrhosis. In adults, ACLF has been proposed to 
be stratified in three levels. Stage 1 includes (a) patients 
with single renal impairment (creatinine ≥ 177 μmol/l); 
(b) patients with single organ failure and creatinine 
between 133  µmol/l and 168  µmol/l and/or moderate 
Table 3 Risk factors for liver transplantation (n = 29) versus survival without (n = 63) on day-60
Odds ratio are expressed as 95% (confidence interval). On multivariable analysis, centre effect was not significant (p = 0.13)
ACLF acute-on-chronic liver failure, INR International Normalized Ratio, pCLIF-SOFA Paediatric Chronic Liver Failure-Sequential Organ Failure Assessment score, PELD 
paediatric end-stage liver disease
Characteristics Univariate analysis Multivariable analysis
Odds ratio p value Odds ratio p value
Comorbidity 0.12 (0.04–0.35) 0.001 0.10 (0.03–0.33) 0.001
Growth failure 2.02 (0.76–5.39) 0.158
ACLF 9.01 (2.55–31.78) 0.001 5.02 (1.24–20.23) 0.023
Sepsis 1.74(0.71–4.25) 0.225
Biliary atresia 1.37 (0.56–3.34) 0.485
INR ≥ 2.5 2.71 (1.04–7.08) 0.041
Bilirubin ≥ 300 μmol/L 2.02 (0.72–5.61) 0.177
pCLIF‑SOFA 1.19 (1.03–1.38) 0.016
pCLIF‑SOFA ≥ 7 2.85 (1.06–7.64) 0.036 5.07 (1.47–17.47) 0.010
PELD 1.05 (1.00–1.13) 0.021
Table 4 Risk factors for  mortality (n = 33) versus  survival 
(n = 97) on day-28
Odds ratio are expressed as 95% (confidence interval)
ACLF acute-on-chronic liver failure, BA biliary atresia, INR International 
Normalized Ratio, pCLIF-SOFA Paediatric Chronic Liver Failure-Sequential Organ 
Failure Assessment score, PELD paediatric end-stage liver disease
Characteristics Univariate analysis Multivariable analysis
Odds ratio p 
value
Odds ratio p value
Growth failure 1.19 (0.48–2.94) 0.69
ACLF 5.68 (1.57–20.5) 0.008 5.41 (0.75–38.6) 0.092
Sepsis 3.17 (1.34–7.49) 0.009 3.85 (0.82–18.12) 0.087
BA 2.05 (0.87–4.82) 0.098




pCLIF‑SOFA 1.52 (1.27–1.81) 0.000 1.76 (1.40–2.20) 0.000
PELD 1.08 (1.03–1.12) 0.000
Table 5 Risk factors for  composite outcome (n = 67) 
versus  survival without  liver transplantation (n = 63) 
on day-60
Odds ratio are expressed as 95% (Confidence Interval). On multivariable analysis, 
centre effect was not significant (p = 0.44)
ACLF acute-on-chronic liver failure, INR International Normalized Ratio, pCLIF-
SOFA Paediatric Chronic Liver Failure-Sequential Organ Failure Assessment score, 
PELD paediatric end-stage liver disease
Characteristics Univariate analysis Multivariable analysis
Odds ratio p 
value
Odds ratio p value
Comorbidity 0.31 (0.15–0.64) 0.002 0.16 (0.05–0.52) 0.003
Growth failure 1.88 (0.84–4.16) 0.12
ACLF 5.8 (1.86–18.32) 0.002 2.83 (0.77–11;11) 0.135
Sepsis 2.7(1.3–5.62) 0.005 2.1 (0.78–5.58) 0.137
Biliary atresia 1.5 (0.76–3.06) 0.23




pCLIF‑SOFA 1.3 (1.18–1.5) 0.000 1.48 (1.25–1.76) 0.019
PELD 1.07 (1.03–1.13) 0.000
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HE, or (c) patients with EH grade 3 or 4 and creati-
nine between 133  µmol/l and 168  µmol/l. Stage 2 and 
3 includes patients with two or three organs failure, 
respectively. Mortality at day-28 is increasing along 
with the stage grade to reach 32% and 76% in stage 2 
and 3, respectively [11]. Derived and validated from 
this above mentioned study, the Chronic Liver Failure-
Consortium ACLF (CLIF-C ACLF) score is a clinically 
relevant scoring system that can be used sequentially to 
stratify the risk of mortality in ACLF patient [18]. Many 
scores have attempted to predict outcome in patients 
with decompensated cirrhosis. The CLIF-SOFA score 
seems to be the most reliable. In a prospective cohort 
of 62 adult cirrhotic patients admitted in ICU, eight 
scoring tools were evaluated (including MELD and 
APACHE II). The CLIF-SOFA had the best accuracy 
with an AUC of 0.75 (0.62–0.88) confirming larger ret-
rospective cohort of 635 patients and a meta-analysis of 
13 studies involving over 2500 patients [1, 14]. In chil-
dren with advanced cirrhosis, the PELD score is widely 
used as a reference score for organ allocation in many 
countries [9, 18]. In contrast to the previous single-
centre study suggesting that pCLIF-SOFA had a pre-
dictive value for mortality outperforming Child–Pugh 
and PELD score, our study showed similar performance 
between pCLIF-SOFA and PELD for 28-day mortality 
prediction [5]. In addition we showed that a pCLIF-
SOFA ≥ 9 had a high accuracy for predicting 28-day 
mortality.
Salvage liver transplantation in critically ill cirrhotic 
patients with multiple organ failure demonstrates excel-
lent outcome even though the transplant window is 
extremely narrow [19]. Data on paediatric ACLF are 
scarce and, due to heterogeneity in the definitions used 
in comparison to EASL-CLIF adult criteria, remain chal-
lenging. Our study shows that ACLF was present in 18% 
of the population. It is consistent with the adult’s preva-
lence of 26% [20], and is close to the only paediatric study 
single-centre report from India (APASL definition) of 
11% rate [21]. In our study, patients presenting ACLF 
were more likely to die or be transplanted (OR 17.7 95% 
CI [4.79–65.7], p < 0.05). Importantly, no patients who 
were transplanted died during the 28 and 60 days follow-
ing PICU admission. The main finding of our study is the 
identification of a pCLIF-SOFA score ≥ 7 at admission as 
accurate criteria to identify from all alive patients, those 
who were transplanted at day-28 and -60.
Beside the pCLIF-SOFA, AKI is an important risk 
factor for mortality in our study (Additional file  2). 
Both AKI stage 1 + 2 and 3 are associated with 28-day 
mortality (data not shown). This association was 
also observed in a previous study where the mortality 
reached 53% in patients with AKI associated with ACLF 
[6]. The pathophysiology is likely to be multifactorial 
(HRS, hypoperfusion, nephrotoxic drugs) warranting 
special consideration in the use of nephrotoxic drugs 
upon admission in order to avoid HRS [22].
In contrast to adult studies that showed strength 
association between sepsis and mortality in critically 
ill cirrhotic patients, in our study sepsis was not sig-
nificantly associated with mortality. In adults, the most 
severe cases with septic shock, mortality was between 
65 to 100% [11, 23]. Data from the prospective CUB-
REA study regrouping 32 French adult ICU over a 
12-year period, showed that cirrhosis was a risk factors 
for death in septic shock patients [24]. In our study, SBP 
due to Gram-negative bacteria was the most common 
infection. Similarly, another paediatric study showed 
that SBP, mainly due to Escherichia coli, is related to 
a 39% in-hospital mortality [25]. In adults, SBP is rec-
ognized as an independently factors associated to 
ICU mortality [23]. Liver failure shares many simi-
larities with sepsis with regard to acute inflammation 
and development of immunoparalysis [26]. Systemic 
inflammation may be involved in the pathogenesis of 
ACLF and be a prognostic factor for evolution towards 
ACLF in patients with acutely decompensated cirrho-
sis [27, 28]. Although not analysed in detail, presence 
of comorbidities in our cohort was associated with all 
outcomes, but 28-day mortality. This goes along with 
observations in critically ill children where comorbidi-
ties are known major prognostic factors in multiple 
clinical conditions.
Our study has several strengths and limitations. It is 
the first paediatric collaborative study including four of 
the largest European paediatric transplant centres. At 
the same time, the retrospective study design may limit 
the generalization of the identified prognostic factors 
although they are consistent with adult data. As such, 
prospective validation is warranted. Second, inhomo-
geneous practice among the participating centres due 
to heterogeneity of both diagnostic and therapeutic 
approach including transplantation criteria cannot be 
ruled out. We have attempted to minimize this bias by 
selecting the largest paediatric European transplant cen-
tres, thereby reducing intrinsic variability as shown in 
previous multicentre paediatric studies involving patients 
with liver diseases.
Conclusion
In this first published multicentre retrospective analysis, 
cirrhotic paediatric patients admitted to PICU are shown 
to have a severe prognosis. On admission, pCLIF-SOFA 
is a reliable score for identifying patients transplanted 
at day-28 and day-60 to those alive without LT and is 
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associated with 28-day mortality and 60-day composite 
outcome.
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